DMD-associated Dilated Cardiomyopathy research hub

Repurposing Empagliflozin for DMD-associated Cardiomyopathy in Children 6-18 Years of Age

This study looks at a new use for an existing medicine, empagliflozin, for children aged 6-18 with heart problems caused by Duchenne muscular dystrophy (DMD). It aims to find the right dose and check if it's safe and helpful for their hearts.